Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26689402 | 1.00 | BLM (0.38) | BLMPMP22HSD17B10PDK2HDAC6 | |
| SCHEMBL22276510 | 0.90 | PDK2 (0.40) | BLMPMP22HSD17B10PDK2HDAC6 | |
| SCHEMBL22276649 | 0.90 | PDK2 (0.40) | BLMPMP22HSD17B10PDK2HDAC6 | |
| SCHEMBL21458597 | 0.87 | BLM (0.38) | BLMPMP22HSD17B10PDK2HDAC6 | |
| SCHEMBL30379736 | 0.87 | BLM (0.38) | BLMPMP22HSD17B10PDK2HDAC6 | |
| SCHEMBL28504242 | 0.87 | PDK2 (0.36) | BLMPMP22HSD17B10PDK2HDAC6 | |
| SCHEMBL21458928 | 0.87 | BLM (0.38) | BLMPMP22HSD17B10PDK2HDAC6 | |
| SCHEMBL24340623 | 0.85 | CA14 (0.40) | BLMPMP22HSD17B10HDAC6L3MBTL1 | |
| SCHEMBL1578129 | 0.84 | MEN1 (0.40) | PDK2HDAC6HDAC1HDAC2GBA1 | |
| SCHEMBL4700714 | 0.83 | PDK2 (0.37) | BLMPMP22HSD17B10PDK2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| EP-2470547-B1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2470547-B1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| EP-2483279-A1 | NEW MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| EP-2470547-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI (FR) | 2012-07-04 | — | — | EP | disclosed |
| EP-2448929-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011039721-A1 | NEW MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039721-A1 | NEW MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011023883-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023883-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | BLM 2116/4885PMP22 1935/4885HSD17B10 1100/4885 |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | GABRA4, GABRP, GABRA1 | BLM 2294/4885PMP22 1856/4885HSD17B10 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.